Wellington Management Group LLP Acquires 335,658 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Wellington Management Group LLP boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,076,426 shares of the medical research company's stock after acquiring an additional 335,658 shares during the quarter. Wellington Management Group LLP owned 7.97% of Charles River Laboratories International worth $752,508,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $601,000. JPMorgan Chase & Co. increased its position in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after purchasing an additional 85,759 shares in the last quarter. State Street Corp lifted its stake in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Janus Henderson Group PLC boosted its position in Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after buying an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new stake in shares of Charles River Laboratories International during the third quarter worth $966,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Charles River Laboratories International Trading Down 2.9 %

CRL traded down $4.03 during trading on Friday, reaching $136.95. 1,666,195 shares of the stock traded hands, compared to its average volume of 771,482. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock's 50-day moving average is $162.49 and its 200 day moving average is $180.77. Charles River Laboratories International, Inc. has a 12 month low of $132.99 and a 12 month high of $258.56. The stock has a market capitalization of $7.00 billion, a PE ratio of 912.99, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.46 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Activity

In other news, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Foster bought 6,075 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CRL shares. UBS Group reissued a "neutral" rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday, December 13th. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).